Uncovering the action mechanism of homoharringtonine against colorectal cancer by using network pharmacology and experimental evaluation

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691.
   PubMed Web of Science ®Google Scholar
• Zhang L, Cao F, Zhang G, et al. Trends in and predictions of colorectal cancer incidence and mortality in China from 1990 to 2025. Front Oncol. 2019;9:98.
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103.
   PubMed Web of Science ®Google Scholar
• Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. Ann Transl Med. 2019;7(21):609.
   PubMed Web of Science ®Google Scholar
• Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394(10207):1467–1480.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Dutta S, Mahalanobish S, Saha S, et al. Natural products: an upcoming therapeutic approach to cancer. Food Chem Toxicol. 2019;128:240–255.
   PubMed Web of Science ®Google Scholar
• Goyal S, Gupta N, Chatterjee S, et al. Natural plant extracts as potential therapeutic agents for the treatment of cancer. Curr Top Med Chem. 2017;17(2):96–106.
   PubMed Web of Science ®Google Scholar
• Sun Q, He M, Zhang M, et al. Traditional Chinese medicine and colorectal cancer: implications for drug discovery. Front Pharmacol. 2021;12:685002.
   PubMed Web of Science ®Google Scholar
• Lü S, Wang J. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J Hematol Oncol. 2014;7(1):2.
   PubMedGoogle Scholar
• Zhu M, Gong Z, Wu Q, et al. Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated β-catenin loss in hepatocellular carcinoma. Cell Death Dis. 2020;11(8):632.
   PubMed Web of Science ®Google Scholar
• Yakhni M, Briat A, El Guerrab A, et al. Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance. Am J Cancer Res. 2019;9(5):1043–1060.
   PubMed Web of Science ®Google Scholar
• Tang JF, Li GL, Zhang T, et al. Homoharringtonine inhibits melanoma cells proliferation in vitro and vivo by inducing DNA damage, apoptosis, and G2/M cell cycle arrest. Arch Biochem Biophys. 2021;700:108774.
   PubMed Web of Science ®Google Scholar
• Weng TY, Wu HF, Li CY, et al. Homoharringtonine induced immune alteration for an efficient anti-tumor response in mouse models of non-small cell lung adenocarcinoma expressing Kras mutation. Sci Rep. 2018;8(1):8216.
   PubMedGoogle Scholar
• Park M, Kwon HJ, Kim SH. Homoharringtonine induces apoptosis in human colorectal carcinoma HCT116 cells via downregulation of Wnt/β-Catenin signaling cascade. Bull Korean Chem Soc. 2019;40(2):196–199.
   Web of Science ®Google Scholar
• Shi X, Zhu M, Gong Z, et al. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways. Food Chem Toxicol. 2020;136:110960.
   PubMed Web of Science ®Google Scholar
• Poornima P, Kumar JD, Zhao Q, et al. Network pharmacology of cancer: from understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacol Res. 2016;111:290–302.
   PubMed Web of Science ®Google Scholar
• Kibble M, Saarinen N, Tang J, et al. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat Prod Rep. 2015;32(8):1249–1266.
   PubMed Web of Science ®Google Scholar
• Chen L, Ren LQ, Liu Z, et al. Bio-informatics and in vitro experiments reveal the mechanism of schisandrin a against MDA-MB-231 cells. Bioengineered. 2021;12:7678–7693.
   PubMed Web of Science ®Google Scholar
• Wang X, Shen Y, Wang S, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45(W1):W356–W360.
   PubMed Web of Science ®Google Scholar
• Yao ZJ, Dong J, Che YJ, et al. TargetNet: a web service for predicting potential drug-target interaction profiling via multi-target SAR models. J Comput Aided Mol Des. 2016;30:413–424.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47:W357–W364.
   PubMed Web of Science ®Google Scholar
• Stelzer G, Rosen N, Plaschkes I, et al. The genecards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinf. 2016;54:1.30.31–31.30.33.
   PubMedGoogle Scholar
• Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48:D845–D855.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang S, Li F, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 2020;48:D1031–D1041.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D1082.
   PubMed Web of Science ®Google Scholar
• Cao W, Liu Y, Zhang R, et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci Rep. 2015;5(1):8477.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang R, Huang D, et al. Homoharringtonine exerts anti-tumor effects in hepatocellular carcinoma through activation of the hippo pathway. Front Pharmacol. 2021;12:592071.
   PubMed Web of Science ®Google Scholar
• Pectasides E, Bass AJ. ERBB2 Emerges as a new target for colorectal cancer. Cancer Discov. 2015;5(8):799.
   PubMed Web of Science ®Google Scholar
• Zhao B, Wang L, Qiu H, et al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget. 2017;8(3):3980–4000.
   PubMedGoogle Scholar
• AsghariHanjani N, Vafa M. The role of IGF-1 in obesity, cardiovascular disease, and cancer. Med J Islam Repub Iran. 2019;33:56.
   PubMedGoogle Scholar
• Hu J, Liu X, Chi J, et al. Expressions of IGF-1, ERK, GLUT4, IRS-1 in metabolic syndrome complicated with colorectal cancer and their associations with the clinical characteristics of CRC. Cancer Biomark. 2018;21:883–891.
   PubMed Web of Science ®Google Scholar
• Jin W. Regulation of Src family kinases during colorectal cancer development and its clinical implications. Cancers (Basel). 2020;12:1339.
   PubMed Web of Science ®Google Scholar
• Kodaz H, Kostek O, Hacioglu MB, et al. Frequency of RAS mutations (KRAS, NRAS, HRAS) in human solid cancer. Breast Cancer. 2017;7:1–7.
   Google Scholar
• Zhou M, Liu X, Li Z, et al. Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells. Int J Cancer. 2018;143(4):921–930.
   PubMed Web of Science ®Google Scholar
• Yuan J, Dong X, Yap J, et al. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13:113.
   PubMed Web of Science ®Google Scholar
• Jiang N, Dai Q, Su X. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47(6):4587–4629.
   PubMed Web of Science ®Google Scholar
• Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125–132.
   PubMed Web of Science ®Google Scholar
• Narayanankutty A. PI3K/ Akt/ mTOR pathway as a therapeutic target for colorectal cancer: a review of preclinical and clinical evidence. Curr Drug Targets. 2019;20(12):1217–1226.
   PubMed Web of Science ®Google Scholar
• Liu HY, Dong TX, Li ZZ, et al. Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway. Neoplasma. 2021;68(5):924–937.
   PubMed Web of Science ®Google Scholar
• Chen P, Wen X, Wang B, et al. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft. Ann Hematol. 2018;97(5):865–875.
   PubMed Web of Science ®Google Scholar
• Yuan R, Hou Y, Sun W, et al. Natural products to prevent drug resistance in cancer chemotherapy: a review. Ann N Y Acad Sci. 2017;1401(1):19–27.
   PubMed Web of Science ®Google Scholar